Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising.
For biotechnology investors, a clear path to the clinic can be one of the most important indicators of a company’s development potential. In oncology, where programs often face significant scientific, regulatory and financial hurdles, companies that demonstrate measurable progress across manufacturing, preclinical testing and operational execution may be better positioned to advance promising therapies.
Beyond scientific validation, access to capital is another critical component of clinical development. Drug candidates require substantial resources to move from discovery through regulatory milestones and into human studies, making strategic financing an important factor in sustaining momentum.
This combination of scientific progress and operational execution is particularly important in oncology, where therapies addressing difficult-to-treat cancers and treatment resistance can represent significant opportunities if successfully developed.
One company working to advance this transition is Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H), a preclinical-stage precision oncology company focused on developing therapies targeting DNA Damage Response (“DDR”) pathways.
The company’s lead candidate, ONC010, is a nanoparticle-encapsulated Polynucleotide Kinase Phosphatase (“PNKP”) inhibitor designed to interfere with DNA repair mechanisms that cancer cells rely on for survival and resistance.
Building the Foundation for Clinical Development
Onco-Innovations has recently achieved several milestones designed to support the continued development of ONC010. The company completed a successful 300-gram active pharmaceutical ingredient (“API”) scale-up, achieving approximately 99.3% purity with residual solvents below the limits of detection of the analytical methods employed, representing an important step toward establishing scalable manufacturing capabilities.
The company has also expanded its manufacturing and formulation capabilities through strategic collaborations, including its partnership with Nanosoft Polymers to support the development, optimization and scaling of the polymer manufacturing process used for ONC010.
Additional development activities include metabolism studies, analytical characterization, exclusive licensing agreements supporting intellectual property protection, and other IND-enabling studies designed to advance the program toward regulatory submission.
Capital Formation Supports Continued Advancement
Alongside these scientific and manufacturing milestones, Onco-Innovations has continued strengthening the financial foundation needed to support its clinical strategy.
The company recently announced an institutional funding arrangement representing a notional subscription amount of approximately CAD$5 million. The financing structure is intended to support key development priorities, including advancing ONC010 through manufacturing and preclinical activities, further development of the SynoGraph(TM) platform, and general corporate purposes.
For emerging biotechnology companies, securing capital ahead of major clinical milestones can be an important step in maintaining development timelines. The arrangement is structured to release proceeds across eighteen monthly tranches against a benchmark price, so the amount ultimately realized may be more or less than the notional subscription amount. By combining this financing structure with continued progress across manufacturing and IND-enabling activities, Onco-Innovations is working to establish the infrastructure needed to support its transition toward human trials.
Preparing for the Next Stage
Onco-Innovations has also strengthened its leadership team with the appointment of Dave Antony as Chief Financial Officer. Antony brings more than 35 years of experience spanning financial planning, reporting, corporate finance, governance and public company advisory matters.
With manufacturing advancements, regulatory preparation, strategic partnerships and a financing structure in place, Onco-Innovations is continuing to build the foundation required for the next stage of ONC010 development, which includes the continuation of its IND-enabling studies in support of a planned Phase 1 program in Australia.
For more information, visit https://oncoinnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease…
A recent study that was conducted on 5,617 people diagnosed with colorectal cancer found that…
Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid…
A preclinical study conducted by a joint team from Switzerland has found that treatment outcomes for glioblastoma…
As GLP-1 use has exploded in the U.S., many companies have started discontinuing coverage of…
Earth Science Tech recently completed the acquisition of Zoolzy LLC, a wholesale distributor of active…